Newswise — FORT WASHINGTON, PA — According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy. [1]
The National Comprehensive Cancer Network® (NCCN®) has published NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia, the newest addition to the library of NCCN Guidelines for Patients®. The NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia, through the support of the NCCN Foundation®, is available to view and download free-of-charge at NCCN.org/patients; for information about print copies, visit NCCN.org/patients.
“Acute Lymphoblastic Leukemia is a very aggressive disease and patients are faced with a multitude of decisions in a short period of time,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “NCCN hopes that this resource will help patients and their caregivers make well-informed decisions about their care.”
For ease of use, the NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia is organized by distinct patient populations—age group [adolescent and young adult (ages 15 – 39) vs. older adult (ages 40+)] and presence of the Philadelphia chromosome.
NCCN Guidelines for Patients®, translations of the NCCN Guidelines®, are designed to provide people with cancer and their caregivers state-of-the-art treatment information in easy-to-understand language. The NCCN Guidelines are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms that address appropriate management options from initial work-up throughout the course of the disease.
NCCN Guidelines for Patients are written according to plain language principles to improve health literacy, and the design and format feature patient-friendly elements such as medical illustrations alongside descriptions of body parts, tests, and treatments. NCCN Guidelines for Patients®: ALL also includes an expansive glossary with definitions of medical terms and acronyms. The NCCN Guidelines for Patients do not replace the expertise and clinical judgment of the physician.
NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia; Caring for Adolescents and Young Adults (AYA); Chronic Myelogenous Leukemia; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma.
To download or order the NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia, visit NCCN.org/patients.
[1]The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia (Version 2.2014). © 2014 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed February 23, 2015. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org.
###
About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients.
RSS